PRESS-RELEASE filed Nov 13, 2026 at 12:10 ET
Oncolytics Biotech entered a clinical supply agreement with Coherus Oncology to evaluate its oncolytic virus pelareorep in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab) in a Phase 2 study for second-line squamous cell anal carcinoma (SCAC). The study is expected to start in Q1 2027 at a U.S. cancer center, targeting patients who have progressed on first-line chemo-immunotherapy. This is a non-dilutive supply deal with no upfront payment or milestone disclosed, providing pelareorep access to a marketed checkpoint inhibitor for a new indication with no approved second-line therapy.